Form 4: Tarsus Pharmaceuticals CFO Sells Shares to Cover Tax Obligations

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, sold shares to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.

Summary

• Jeffrey Farrow, the Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, sold shares of common stock between March 18, 2025, and March 20, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• On March 18, 2025, 1,284 shares were sold at a price of $46.29.
• On March 19, 2025, 1,254 shares were sold at a price of $47.4.
• On March 20, 2025, 1,186 shares were sold at a price of $50.11.
• Following these transactions, Farrow directly owns 22,431 shares of Tarsus Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (selling shares to cover taxes on vested RSUs). It's neutral in sentiment as it doesn't indicate positive or negative performance of the company.

Management Comments

• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives.

Stakeholder Impact

• The sale of shares by the CFO could have a minor, temporary impact on the stock price, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Tarsus Pharmaceuticals, Jeffrey Farrow, Form 4, Share Sale, Tax Withholding, Restricted Stock Units, TARS